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Purpose: Progressive myoclonic epilepsy type one is a neurodegenerative disorder characterized by action- and
stimulus-sensitive myoclonus, tonic–clonic seizures, progressive cerebellar ataxia, preserved cognition, and
poor outcome. The authors report clinical, neurophysiological, radiological, and genetic ﬁndings of an Emirati
family with ﬁve affected siblings and review the literature.
Methods: All data concerning familial and clinical history, neurologic examination, laboratory tests, electroen-
cephalogram, brain imaging, and DNA analysis were examined.
Results: Genetic testing conﬁrmed the diagnosis of autosomal recessive progressive myoclonic epilepsy type 1
(EPM1) in two males and three females. The median age at onset was three years. Action- or stimulus-sensitive
myoclonus and generalized seizures were recorded in 100% of our patients, at median age at onset of 3 and
4 years, respectively. Multisegmental myoclonus and generalized status myoclonicus were observed in 80% of
our patients. Dysarthria and ataxia developed in 100% of our patients. Vitamin D deﬁciency and recurrent viral
infections were noticed in 100% of our cohort. Cognitive, learning, and motor dysfunctions were involved in
100% of our patients. The sphincters were affected in 60% of our patients. Abnormal EEG was recorded in 100%
of our cohort. Generalized brain atrophy progressively occurred in 60% of our patients. Phenytoin and carbamaz-
epine were used in 60% of our patients with worsening effect. Valproate and levetiracetamwere used in 100% of
our patients with improving effect.
Conclusions: This is the ﬁrst to report a family with EPM1 in UAE. Our study emphasized a particular phenotype
expressed as earlier disease onset, severe myoclonus, and generalized seizures. Cognitive, cerebellar, motor, and
autonomic dysfunctions and brain atrophy were also earlier at onset and more severe than previously reported.
Recurrent viral infections are another unique feature. This constellation in tout à fait was not previously reported
in the literature.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Progressive myoclonic epilepsy type 1 (EPM1) or Unverricht–
Lundborg disease (ULD) is an autosomal recessive disorder [1]. It is con-
sidered themost common and less severe form of progressivemyoclon-
ic epileptic syndromes. It was initially recognized in Finland, where
prevalence and incidence are 5 and 4 in 100 000 births, respectively
[2]. Clusters of phenotypically and, sometimes, genetically identical
disorders occur in southern Europe and North Africa [3]. Its prevalence).
.
. This is an open access article underhas recently increased in theMediterranean region [4]. However, recent
studies suggested that it may be underdiagnosed in many countries [5].
Regions of higher prevalence are found in places with common founder
effect or high rates of consanguineous marriages.
Progressive myoclonic epilepsy type 1 starts in children at
6–16 years of age. Its onset is characterized by myoclonic jerks and/or
tonic–clonic seizures. Generalized tonic–clonic seizures are the present-
ing feature inmany cases [6]. Action- or stimulus-sensitivemyoclonus is
an essential feature for diagnosis and the ﬁrst symptom in half of the pa-
tients [7]. It is usually fragmentary and multifocal and is often triggered
by variable stimuli. It is particularly apparent in muscles of the face and
distal limbs. Bilateralmassivemyoclonus tends to involve proximal limb
muscles closest to the torso [6]. This disablingmyoclonus promotes riskthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Demographics and clinical features.
Age Sex Onset EMJ/SSM MultisM StatMyoc GTC Seiz Dysarthria Ataxia
31 y M 2 y 2 y + + 3 y Severe Severe
30 y M 3 y 3 y + + 4 y Severe Severe
18 y F 3 y 3 y + + 4 y Severe Severe
14 y F 3 y 3 y + + 4 y Mild Mild
12 y F 4 y 4 y − − 5 y Mild Mild
EMJ: early morning jerks, SSM: stimulus-sensitive myoclonus, Multis M: multisegmental
myoclonus, Stat Myoc: status myoclonicus, GTC Seiz: generalized tonic–clonic seizures,
y: year, M: male, +: positive, F: female,−: negative.
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nation is normal initially, however, intention tremor, dysarthria, and
ataxia develop later. Mild dementia is typically a late feature. Intellectu-
al deﬁcit develops very late [8].
Electroencephalograph (EEG) demonstrates spontaneous spike and
polyspike–wave complexes, photosensitivity, and background slowing
[1]. Initially, brain MRI is usually normal. It is often mistaken for the
more common juvenile myoclonic epilepsy (JME). However, it is not
currently possible to diagnose EPM1 without a genetic test. Earlier
onset cases often resulted in premature need of wheelchair or death be-
fore their midtwenties [9]. Modern antiepileptic therapy has gradually
increased life expectancy [6]. Phenotypes result from the interaction
of genes and environment. Therefore, it is crucial to determine present-
ing phenotypes, its variability, inﬂuencing factors, and phenotype–
genotype association.We describe clinical, electrophysiological, and ra-
diological aspects, in addition to genetics and management of an
Emirati family, and review relevant literature.
2. Patients and methods
Indexpatients in our family are the second and third, both seen inMay
2004. They belong to an Arabian family consisting of parents and eleven
siblings. Both reported an older siblingmore severely affected, bedbound,
and mentally retarded. Both suffered early morning myoclonic jerks,
stimulus- and action-sensitive myoclonus, and generalized seizures. All
three were the product of a normal pregnancy and uneventful full-term
vaginal delivery. Their parents are ﬁrst-degree cousins. Differential diag-
nosis included PME, JME, idiopathic myoclonic epilepsy, and subacute
sclerosing panencephalitis. Therefore, the indexpatientswere extensively
investigated. Hematologic, metabolic, mineral, endocrine, and vitamin
proﬁles were arranged. Ancillary studies like C-reactive protein, ferritin,
homocysteine, methylmalonic acid, alpha-fetoprotein, hemoglobin elec-
trophoresis, drug levels, ECG, echocardiogram, and Holter monitoring
were done as indicated. Quantitative amino acid testing in urine of
28 amino acids; enzymatic assay of alpha- and beta-galactosidases in
leucocytes, GM1 gangliosidosis, and very long-chain fatty acids including
phytanate and pristanate levels; skin and muscle biopsy with special his-
tochemistry; andmitochondrial DNA (mtDNA) analysis were done in the
ﬁrst and third patients to rule out MERRF. Brain Electroencephalograph,
brain CT, and MRI brain and measles antigen–IgG in the blood and in
CSF were needed. Genetic DNA testing was done ﬁrst in these two pa-
tients using PCR analysis and Southern blotting. When these returned as
positive for the CSTB gene, the other three affected siblings and parents
were tested. The genetic pedigree is shown in Fig. 1. Demographic and
clinical data were tabulated (Tables 1 and 2), further analyzed, and com-
pared with contemporary literature.
3. Results
Genetic testing conﬁrmed the diagnosis of autosomal recessive EPM1
in ﬁve, two males and three females, who constituted our probands. It
was done by taking blood samples from each patient and performingmo-
lecular testing by PCR fragment analysis and genomic Southern blotting.
Polymerase chain reaction (PCR) failed to detect normal CSTB alleles,Fig. 1. Genetic pedigree shows the carrier status of parents and the affected two brothers
and three sisters.whereas Southern blotting revealed expanded alleles with more than
30 dodecamers. Both expanded alleles were estimated to contain a max-
imum of 100–120 repeats in the ﬁrst three patients and aminimumof 80
repeats in the remaining two patients; the highest repeatwas recorded in
our ﬁrst patient. Results conﬁrmed the diagnosis of autosomal recessive
EPM1 in all our probands (100%). Genetic testing was done for both par-
ents, PCR detected normal CSTB signal, whereas Southern blotting re-
vealed normal and expanded allele with 100 dodecamer repeats. The
sequences of CSTB exons including adjacent splice signals correspond to
those of published references [10]. Results conﬁrmed the EPM1 carrier
status of one expanded CSTB allele repeat in each parent. The median
age at onset of diseasewas three (range: 2–4) years (Table 1). Earlymorn-
ingmyoclonic jerks and action- or stimulus-sensitivemyoclonus and gen-
eralized tonic–clonic seizures were recorded in 100% of our patients. The
median age at onset of myoclonus and generalized seizures was also ear-
lier at 3 and 4 years, respectively. Multisegmental myoclonus and gener-
alized status myoclonicus occurred in 80% of our patients. Dysarthria and
ataxiawere observed in 100%of our patients at amean age of 8 years. Fre-
quent and recurrent traumas and notably viral infections were noted in
100% of our patients (Table 2). Severe sphincter dysfunctionwas reported
at a median age of 6 years in 60% of our patients. Cognitive dysfunction
complicated the clinical picture in 100% of our patients at a mean age at
onset of 8 years. Difﬁculty in learning was detected in 100% of our pa-
tients, with 60% of them having moderately severe learning difﬁculty.
Spasticity and motor dysfunction were steadily progressive and involved
100% of our patients at a median age of 7–8 years. Vitamin D deﬁciency
was observed in 100% of our cohort. Electrocardiogram ECG was abnor-
mal in one patient and showed short PR interval, nodal rhythm,mild bra-
dycardia, and paroxysmal atrial ﬁbrillation. EEGwas abnormal in 100% of
our cohort. Brain CT and MRI were initially normal in 80% of our
patients. Central and peripheral brain atrophy gradually progressed in
60% of our patients. The second patient had initially isolated vermian
atrophy. Muscle biopsy to detect striated ragged red ﬁbers and
enzymatic changes in respiratory chain to rule out mitochondrial
encephalopathy with striated ragged red ﬁbers (MERRF), skin biopsy to
detect Lafora bodies, and mitochondrial DNA analysis were done in one
patient each, and all were negative. Phenytoin and carbamazepine were
initially used for only 2–4 months in 60% of our patients with worsening
effect. Valproate, clonazepam, and levetiracetamwere used in 60% of our
patients with seizure improvement. Valproate and levetiracetam were
the sole agents used in 40% of our patients.4. Discussion
This family consisted of parents who are carriers of the CSTB gene
and ﬁve siblings conﬁrmed to have EPM1, twomales and three females.
The median age at onset of the disease was 3 (range: 2–4) years
(Table 1) versus 6–15 years in the published literature [2,11]. This is
an entirely new ﬁnding which was not previously reported in this
common disease mutation in the literature. Early morning myoclonic
jerks and action- or stimulus-sensitive myoclonus were recorded
in all our patients (100%). Myoclonus was the ﬁrst symptom in
100%, and the median age at its onset was 3 years in our cohort.
Table 2
Demographics and complications.
Pat Trauma Infection Cognition Learning D Spasticity M Dysfun Sphincters
31 y M + + MR 3 y Severe Severe 5 y Bbound 5 y 3 y
30 y M + + IQ 76, LSc 8 y Moderate Moderate 7 y Wchair 8 y 7 y
18 y F + + IQ 76, LScD 9 y Moderate Moderate 7 y Wchair 8 y 8 y
14 y F + + IQ 81, 10 y Mild Mild 8 y Mild 9 y −
12 y F + + IQ 82, 10 y Mild Mild 8 y Mild 10 y −
Pat: patient, D: difﬁculty, M Dysfun: motor dysfunction, Y: year, M: male, +: positive, MR: mental retardation, Bbound: bedbound, IQ: Intelligence Quotient, LSc: left school, Wchair:
wheelchair, F: female, LScD: left school of disabled,−: negative.
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over 50% of cases, and the median age at onset was 12.1 years in
published literature [6,9]. Multisegmental, asynchronous myoclo-
nus and status myoclonicus occurred in 80% of our patients
(Table 1). Typically, action- or stimulus-sensitive myoclonus is an
essential feature for diagnosis. Generalized tonic–clonic seizures
were observed in 100% of our cohort at a mean age of 4 (range:
3–5) years. However, they were observed in almost 50% of cases
at a mean age of 10.8 years in the relevant literature [6,11]. Symp-
toms inexorably progressed in one-third of reported patients in
their midtwenties [2,6], while 60% of our family became bedbound
or wheelchair-bound at a mean age of 7 years.
Neurologic examination is initially normal. However, an experi-
enced neurologist clinically pinpoints recurrent, almost cryptic myoclo-
nus in response to various stimuli and actions including photic stimuli,
threats, clapping of hands, and loud noises produced during the exami-
nation. This was observed early in our patients (2–4 years). Dysarthria
and ataxiawere observed in 100% of our patients, with 60% of themhav-
ing a severe form of dysarthria and ataxia comparedwith almost 50% of
patients in literature [6,11] (Table 1).
Frequent and recurrent trauma was one of the most common com-
plications observed in !00% of our cohort and led to various fractures,
joint twists, and strains. An interesting feature which was sparingly
reported is frequent and recurrent notably viral infections in 100% of
our cohort (Table 2). Moderate to severe sphincter dysfunction was
featured in 60% of our patients at a median age of 6 years. Cognitive
dysfunction complicated the clinical picture in 100% of our patients at
a mean age of 8 years, it was particularly severe in the ﬁrst patient
whowasmentally retarded in early childhood and did not attend school
with healthy peers. The second and third patients have moderate and
progressive learningdifﬁculty and left their regular and disabled schools
at 8–9 years. The IQ of both was considered borderline impaired (IQ:
76). Learning difﬁcultywas prominent in 60% of our patients. The fourth
and ﬁfth patients have early learning difﬁculty at 10 years of age with
IQs of 81–82 on Wechsler's intelligence scale which rank them below
low moderate status. Mental retardation is an unusual ﬁnding in
EPM1 [8]. Cognitive dysfunction and progressive learning difﬁculty
were deﬁned as rare and late features. Dementia and intellectual deﬁcit,
if present at all, have been reported to develop very late [2,8]. Spasticity
and motor dysfunction were moderate to severe in 60% of our patients
and observed at median age of 6–7 years (Table 2). Learning and
motor dysfunctions were both steadily progressive andmay have a cer-
tain degree of synchronization. This is entirely different from the pub-
lished literature, as mild dementia and ataxia are typically late
features [6,8]. Curiously 100% of our cohort showed vitamin D deﬁcien-
cy. The exact relation to this phenotype is presently unknown. Pheno-
typic expression is variable, even in the same region, however, this
constellation of unusual multiple clinical features in our family may im-
pose a special and independent phenotype.
Disease course in our cohort seems inevitably progressive. The
phenotype is more heterogeneous than previously assumed. It was no-
ticed previously that only few patients become wheelchair-bound, and
signiﬁcant interpersonal ﬂuctuations will be observed for many years
before losing the ability to walk. In contrary, 60% of our patients lost
their ability to walk within 5–8 years. Variable intensity of symptomsand speed of disease progression can also vary even within the same
family. It was suggested that patients fromFinland andNorthAfrican re-
gions share a common ancient founder effect [12]. Prevalent use of phe-
nytoin in Finnish patients was claimed to be a major factor in clinical
differences between both regions. In our cohort, phenytoin was used
in our ﬁrst three patients for only 2–4 months, and this period cannot
be assumed responsible for changes in our phenotype. Environmental
factors and differences in diet composition stand out as the logic expla-
nation for differences in disease course not only between different
regions but also within the same region or even the same family. How-
ever, this speculative effect on disease phenotype remains to be proven
[13,14]. Progressivemyoclonic epilepsy type 1-like phenotypewith ear-
lier onset, linked to chromosome 12, was described in an inbred Arab
family [15], and the causative gene remained unknown. It was also re-
ported in a North Sea phenotype that the causative gene was GOSR2
[16]. However, our phenotype was positive for classical CSTBmutation.
Laboratory tests were not helpful; however, in working through the
differential diagnosis, biochemical and enzymatic assays become useful
in excluding important masquerades. This was true with our ﬁrst three
patients. ECG in the second patient showed short PR interval, nodal
rhythm, mild bradycardia, and paroxysmal atrial ﬁbrillation. The exact
relationship to EPM1 is not presently known.
Diagnosis should be expected in normally developing 6- to 16-year-
old children who present with action myoclonus, tonic–clonic seizures,
marked photosensitivity, gradual worsening of stability, and normal
cognition [17]. However, such a statement is no longer completely accu-
rate as our family had earlier disease onset and more rapid deteriora-
tion. Differential diagnosis is crucial; if action myoclonus is absent,
patients can be easily misdiagnosed with JME [18]. In exceptionally se-
vere progression of cognitive or visual symptoms, Lafora's disease,myo-
clonic epilepsy with ragged red ﬁbers (MERRF), neuronal ceroid
lipofuscinoses (NCL), and sialidoses should be considered [2].
EEG was abnormal in 100% of our cohort; it showed generalized
polyspike, spike, and slow-wave (GPSSW) complexes in 60% (Fig. 2),
generalized paroxysmal polyspikes and slow waves (GPPSW) in 20%
(Fig. 3), and generalized low amplitude spike and slow wave (GSSW)
complexes in 20% of our patients. The background was normal during
early years of the course. Photosensitivity was prominent. Focal epilep-
tiform changes, in either occipital region, were observed in 40% of our
cohort and reported elsewhere in 25% of patients [11,17].
Therefore, focal changes coexistingwith generalized ﬁndings cannot
exclude EPM1. In addition, physiological sleep patterns disappeared in
60% after 8 years in our cohort compared with those in 50% in the liter-
ature after 16 years of disease [17]. This is different from Lafora's disease
in which disappearance of physiological sleep pattern is an early recog-
nized and constantly progressing feature [6]. Themajority of myoclonic
jerks are not time-locked to EEG discharges. This can lead to the wrong
conclusion of psychogenic seizures [19]. It would be important to study
the EEG features of the current phenotypes at different stages of the
disease.
Brain CT and MRI were completely normal in 40% of our patients.
This is usually observed at the time of diagnosis, while, at later stages,
atrophy of the medulla, cerebellum, pons, midbrain, and, less often,
cerebral hemispheres was observed [4,20]. Mild central and peripheral
atrophy was observed earlier in 60% of our cohort. However, one
Fig. 2. EEG shows frequent paroxysmal generalized bursts of low amplitude spike-and-wave discharges bilaterally and synchronously with a background of diffuse 5–7 theta waves on
both hemispheres.
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evaluation of the imaging ﬁndings of the current phenotypewith differ-
ent disease severity is recommended.
In autosomal recessive EPM1, 74% [21] of all probands showexpand-
ed repeats in both alleles of the cystatin B (CSTB) gene with more than
30 dodecamers, while normal alleles have only 2–3 copies. Other
EPM1-associated CSTB mutations are rare and found in homo or com-
pound heterozygote in 2% [22] of all probands. Progressive myoclonic
epilepsy type 1 is transmitted in an autosomal recessive fashion and isFig. 3. EEG shows generalized polyspikes-and-slowwave complexes with slowing of the backg
the posterior regions.linked to chromosome 21q22.3 [5]. The CSTB gene encoding cystatin B,
a cysteine protease inhibitor, is the only gene known to be associated
with EPM1 [23]. The largest allele recorded worldwide was 125
dodecamer repeats. The largest in our family was 120 repeats and was
observed in the ﬁrst patient. Despite outstanding advances, there is no
convincing explanation of a direct relationship between genetic defects
and the resulting clinical symptoms [6,24]. No detailed evaluation of
phenotype–genotype correlation during the current era has been
performed. However, we noticed that age at onset and severeround of moderate amplitude (50–75 μV) and delta (2 Hz) and theta (5 Hz) particularly in
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largest repeat expansions. Cognitive impairment was also evident
early in all, and the ﬁrst two could not even initiate their normal prima-
ry education. The ﬁrst patient is mentally retarded since his early child-
hood. The second patient had gradual deterioration of his cognition
relatively early in the disease course and ﬁnally culminated in disability
to continue his primary regular learning. The third patient had cognitive
delay since the age of 9 years, and her IQ was 75 which put her in the
category of borderline impairment. The fourth and ﬁfth patients had
IQs of 81 and 82, respectively, and this coincides with the low average
category. Our patients, associated with classical dodecamer repeat ex-
pansionmutation, have a more severe formwith early onset of myoclo-
nus, generalized seizures, ataxia, motor and autonomic dysfunction,
learning difﬁculty, cognitive impairment, brain atrophy, and recurrent
notably viral infections. These ﬁndings may have important implica-
tions in revealing pathogenesis, and, therefore, it is important to achieve
a more detailed evaluation of genotype–phenotype correlations. How-
ever, despite progress in understanding the biological function of
CSTB, disease mechanisms in EPM1 remain elusive [6,25,26].
Pharmacotherapy is the cornerstone of management. There is no spe-
ciﬁc treatment. However, recent advances in antiepileptic drugs im-
proved prognosis [27] signiﬁcantly. Valproate is the ﬁrst drug of choice,
especially if started early [8]. It reduces myoclonus and frequency of gen-
eralized seizures. It was the ﬁrst drug of choice in 80% and the only drug
used in 20% of our patients. Levetiracetam is more effective when given
early [5]. It showed substantial beneﬁt in stimulus-evoked and action-in-
duced myoclonus and generalized seizures [28–30]. It was the second
drug of choice in 80% and the only drug used in 20% of our patients. Clo-
nazepam as an add-on therapy is the only FDA-approved drug for myo-
clonic seizures [12,31]. We used it in 60% of our patients. Primidone and
high-dose piracetam were beneﬁcial in myoclonic seizures, and each
was used in one of our patients. Piracetam was used only to treat myoc-
lonus; however, we noticed that it exacerbated generalized tonic–clonic
seizures. Topiramate and zonisamide were also used as add-on treat-
ments [32]. Topiramate worsened the control of morning jerks and gen-
eralized seizures in one of our patients. Lamotrigine caused increased
sleepiness, tremulousness, and incoordination in one of our patients.
Brivaracetam, an SV2A ligand that differs from levetiracetamby itsmech-
anism of action proﬁle, showed signiﬁcant antiepileptic activity in exper-
imental models of epilepsy and myoclonus [33,34]. It is currently being
investigated as an add-on treatment in adolescents and adults. Ketogenic
diet was tried in one of our patients with no appreciable beneﬁts. Vagus
nerve [35] and subthalamic deepbrain [36] stimulation have been report-
ed to diminish generalized seizures and myoclonus, respectively.
Phenytoin should be avoided as it aggravates myoclonus and pro-
vokes cerebellar degeneration and atrophy. Carbamazepine, oxcarba-
zepine, tiagabine, vigabatrin, gabapentin, and pregabalin should be
avoided as they may exacerbate myoclonus and myoclonic seizures
[37]. Phenytoin and carbamazepine worsened myoclonus in 60% of
our patients. However, both were used for not more than 2–4 months,
which makes it unlikely that it affected clinical and radiological
outcome. In settings of recurrent, massive myoclonus or status
myoclonicus, loud noises and bright lights should be avoided, and the
patient should be nursed in a quiet room. Intensive acute treatment in-
cludes intravenous use of lorazepam, clonazepam, diazepam,midazolam,
valproate, and levetiracetam. Phenytoin and fosphenytoin should be
avoided. General anesthesia is rarely needed.
In conclusion, our study emphasized a particular phenotype of this
disease consisting of earlier disease onset, debilitating myoclonus, gen-
eralized seizures, prominent cognitive dysfunction and learningdifﬁcul-
ty, and earlier onset and rapid progression of motor, cerebellar, and
autonomic dysfunction, brain atrophy, and recurrent viral infections.
Although, many of the individual components of this phenotype were
discussed in the literature, this particular constellation in tout à fait
was not previously coined; therefore, this is a peculiar phenotype, and
further research may shed light on this issue.Disclosure
The authors have nothing to disclose.References
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